BIOPHYTIS Aktie
| 0,02EUR | 0,00EUR | -4,22% |
WKN DE: A403QV / ISIN: FR001400OLP5
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 26 | 25 | 22 | 20 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 32 | 19 | 9 | 4 | 0 |
| Summe Anlagevermögen | 4 | 3 | 3 | 3 | 0 |
| Summe Aktiva | 36 | 22 | 12 | 7 | 0 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 31 | 24 | 16 | 17 | 0 |
| Summe Eigenkapital | 6 | -2 | -4 | -10 | 9 |
| Summe Passiva | 36 | 22 | 12 | 7 | 0 |
Adresse
| Sorbonne Université, 75005 Paris | |
| Telefon | +33 (1) 44-27-23-00 |
| Internet | http://www.biophytis.com |
Management
|
Chiara Baccelli
Chief Pharmaceutical Operations Officer |
|
Claude Allary
Independent Director |
|
Claudia Ferreira
Medical Director |
|
Edouard Bieth
Chief Business Officer |
|
Jean Mariani
Director |
|
Nadine Coulm
Independent Director |
|
Nicolas Fellmann
Chief Financial Officer & Head-Investor Relations |
|
Pierre J. Dilda
Chief Scientific Officer |
|
Rob van Maanen
Chief Medical Officer |
|
Stanislas Veillet
Chairman, President & Chief Executive Officer |
|
Waly Dioh
Chief Clinical Operating Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.